Sign In
Last checked at 
10 Jan 2022 07:00
IXICO plc
("IXICO" or the "Company")
Grant of share options
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has granted 300,000 options over the ordinary shares in the Company in accordance with the rules of the Company's EMI Share Option Plan 2014 (the 'Plan') exercisable at a share price of 1p.
These options are subject to performance conditions linked to compound share price growth across three years. Robin Wolz, Chief Scientific Officer, Romina Oxborough, SVP Operations and Chris Hamilton, SVP Commercial who are all considered PDMRs as members of the IXICO Senior Leadership Team, each receive 100,000 options under this award.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Robin Wolz | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Scientific Officer | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| IXICO plc | |||
b)
| LEI
| 2138005M1F59O6HWSA97 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares in IXICO plc | |||
Identification code | GB00BCLY7L40 | ||||
| |||||
b)
| Nature of the transaction
| Grant of share options
| |||
c)
| Price(s) and volume(s) |
|
|
|
|
| Price(s) | Volume(s) |
| ||
| 1p | 100,000 |
| ||
|
|
|
| ||
d)
| Aggregated information | N/A | |||
- Aggregated volume | |||||
- Price | |||||
e)
| Date of the transaction
| 10 January 2022 | |||
f)
| Place of the transaction
| Off market | |||
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Romina Oxborough | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| PDMR (SVP Operations) | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| IXICO plc | |||
b)
| LEI
| 2138005M1F59O6HWSA97 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares in IXICO plc | |||
Identification code | GB00BCLY7L40 | ||||
| |||||
b)
| Nature of the transaction
| Grant of share options
| |||
c)
| Price(s) and volume(s) |
|
|
|
|
| Price(s) | Volume(s) |
| ||
| 1p | 100,000 |
| ||
|
|
|
| ||
d)
| Aggregated information | ||||
- Aggregated volume | N/A | ||||
- Price | |||||
e)
| Date of the transaction
| 10 January 2022 | |||
f)
| Place of the transaction
| Off market | |||
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Chris Hamilton | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| PDMR (SVP Commercial) | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| IXICO plc | |||
b)
| LEI
| 2138005M1F59O6HWSA97 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares in IXICO plc | |||
Identification code | GB00BCLY7L40 | ||||
| |||||
b)
| Nature of the transaction
| Grant of share options
| |||
c)
| Price(s) and volume(s) |
|
|
|
|
| Price(s) | Volume(s) |
| ||
| 1p | 100,000 |
| ||
|
|
|
| ||
d)
| Aggregated information | N/A | |||
- Aggregated volume | |||||
- Price | |||||
e)
| Date of the transaction
| 10 January 2022 | |||
f)
| Place of the transaction
| Off market | |||
For further information please contact:
IXICO plc | +44 (0)20 3763 7498 | |||
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |||
| ||||
Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |||
Giles Balleny / Max Gould (Corporate Finance) |
| |||
Michael F Johnson / Russell Kerr (Sales) |
| |||
| ||||
Walbrook PR Ltd | Tel: 020 7933 8780 or IXICO@walbrookpr.com
| |||
Paul McManus / Lianne Applegarth / | Mob: 07980 541 893 / 07584 391 303 / | |||
Alice Woodings | 07407 804 654 | |||
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
Follow the stocks
